Introduction
============

Management of early breast cancer involves a multimodality approach employing surgery, radiotherapy (RT), chemotherapy, and hormonal therapy, requiring considerable health care resources. For women undergoing breast-conserving surgery, standard fractionation radiotherapy results in excellent cosmesis in most cases (Shafiq et al., [@B19]), and a recent meta-analysis from 17 randomized trials demonstrates that it produces a 15.7% reduction in the 10-years risk of any first recurrence and results in a 3.8% absolute reduction of breast cancer death at 15 years (Darby et al., [@B5]).

To enhance adherence and reduce costs, strategies have been developed to reduce the overall treatment time and number of visits to the radiation facilities, using accelerated treatment schedules which increase the dose per fraction and/or a concomitant boost (CB) to the tumor bed (Formenti et al., [@B7]; van der Laan et al., [@B26]; Jalali et al., [@B13]).

The general rationale for including a boost to the tumor bed is based on 10 years results of the European Organization for Research and Treatment of Cancer (EORTC) "boost/no boost" trial that demonstrated a reduction in local recurrence rate when a 16-Gy boost was included (6.2 vs. 10.2%, *P* \< 0.0001; Poortmans et al., [@B17]). CB via IMRT improves dose conformality to the breast and boost regions while allowing for the delivery of a larger dose per fraction to the area at high risk of residual microscopic cancer. The concomitant technique shortens the radiotherapy course by 1--3 weeks while maintaining the biological benefit of a dose increment at the tumor bed site.

Little comparative data with regards to toxicity amongst different fractionation approaches is available for the treatment of breast cancer, particularly in the prone position. To our knowledge, no prospective randomized studies have compared daily radiotherapy over 3 or 5 weeks with a CB to the tumor bed to the standard 6 weeks regimen that includes a consecutive boost.

We identified in our database a consecutive group of patients who had undergone breast-conservation surgery and who, at initial consultation for post-operative radiotherapy, were offered, based on their tumor characteristics, to choose among three approaches: standard 6 week radiation therapy with a sequential boost (6wSB), a regimen of 5 weeks of daily radiotherapy with a CB using IMRT (5wCB) or a protocol of 3 weeks daily radiotherapy with a CB using IMRT (3wCB), respectively. Each patient was first offered standard therapy and then informed about the two accelerated regimens. Patient's preference dictated the choice of treatment, as documented in the medical record. We compare acute and late toxicity outcomes for patients treated on the three regimens.

Materials and Methods
=====================

Study design and eligibility
----------------------------

The study was approved by the NYU Institutional Review Board and the collection, storage, and retrieval of data were all done in compliance with the Health Insurance Privacy and Portability Act. The consecutive cohort was defined as Stage I--II breast cancer patients who, after segmental mastectomy with negative margins, were offered the choice to undergo whole breast radiotherapy either with a standard fractionation regimen of 6 weeks that included a sequential boost (SB) to the tumor bed or with a hypo-fractionation regimen of 3 or 5 weeks with IMRT to deliver a CB to the tumor bed. Patients were identified from the departmental record and verify databases (ARIA, Varian Medical System, Palo, Alto, CA, USA).

A total of 169 consecutive patients with the above characteristics were identified. In 159/169 patients a documented follow up visit, at least a year after completing radiotherapy was available for evaluation of late effects.

Radiobiologic rationale for dose and fractionation schedule
-----------------------------------------------------------

The 6-week schedule (6wSB) prescribed 60 Gy in 30 fractions of 2 Gy over 6 weeks: the first 23 fractions targeting the whole breast prone, followed by the remaining 7 fractions targeting the tumor bed with an electron boost field, set-up in supine position. The 5-week CB schedule (5wCB) delivered 50 Gy in 25 fractions of 2 Gy to the prone breast, with a daily CB of 25 cGy to the tumor bed, over a total of 5 weeks. Finally, the 3 week CB schedule (3wCB) delivered a total dose of 40.5 Gy, at 2.7 Gy in 15 fractions to the prone breast with an additional CB of 0.5 Gy delivered to the tumor bed, for a total dose of 48 Gy to the lumpectomy site. The results of the latter regimen were previously reported (DeWyngaert et al., [@B6]; Formenti et al., [@B7]).

The linear-quadratic model (Fowler, [@B8]) was used to determine whether the proposed accelerated intensity-modulated RT (AIMRT) protocol yields a roughly equal probability of tumor control compared with a standard schedule, using a tumor α/β of 4. This is the same α/β value that Owen et al. ([@B16]) derived based on UK National Cancer Research Institute (NCRI) randomized trial which evaluated three dose schedules for breast cancer treatment. BEDs for the standard and accelerated IMRT schedules were calculated, as previously described (DeWyngaert et al., [@B6]), assuming that full repair takes place during the ≥24-h interval between fractions.

Table [1](#T1){ref-type="table"} lists the BEDs for tumor control, early responses to radiation effects (erythema and desquamation), and late responses (telangiectasia and fibrosis) for the three fractionation schedules. The choices for the α/β values used for these computations have been justified in previous studies (Steel et al., [@B22]; Matthews et al., [@B15]; Turesson and Thames, [@B25]; Thames et al., [@B23]; Archambeau et al., [@B1]; Yamada et al., [@B29]).

###### 

**Biologically equivalent doses for late effects and tumor control**.

  ---------------------------------------------------------------------------------------------------------------------
                      α/β (Gy)       6WSB Schedule\*\           5wCB Schedule^†^\          3wCB Schedule^††^\
                                     2 Gy × 23 in 39 days       2 Gy × 25 in 32 days       2.7 Gy × 15 in 18 days
  ------------------- -------------- -------------------------- -------------------------- ----------------------------
  **LATE EFFECTS**                                                                         

  Fibrosis            2              92 Gy~2~                   100 Gy~2~                  95 Gy~2~

  Telangiectasia      4              69 Gy~4~                   75 Gy~4~                   68 Gy~4~

  Erythema            8              58 Gy~8~                   63 Gy~8~                   54 Gy~8~

  Desquamation        11             54 Gy~11~                  59 Gy~11~                  50 Gy~11~

                                                                                           

                      **α/β (Gy)**   **6WSB Schedule**\         **5wCB Schedule**\         **3wCB Schedule**\
                                     **2 Gy × 23 in 39 days**   **2 Gy × 25 in 32 days**   **3.2 Gy × 15 in 18 days**

                                                                                           

  **TUMOR CONTROL**                                                                        

  Tumor               2              120 Gy~2~                  120 Gy~2~                  125 Gy~2~

  Tumor§              2              116 Gy~2~                  118 Gy~2~                  125 Gy~2~

  Tumor               4              90 Gy~4~                   88 Gy~4~                   86 Gy~4~

  Tumor§              4              86 Gy~4~                   86 Gy~4~                   86 Gy~4~

  Tumor               10             72 Gy~10~                  69 Gy~10~                  63 Gy~10~

  Tumor§              10             68 Gy~10~                  67 Gy~10~                  63 Gy~10~
  ---------------------------------------------------------------------------------------------------------------------

*\*6wSB, 6-Week sequential boost; ^†^5wCB, 5-week concomitant boost; ^††^3wCB, 3-week concomitant boost; §, taking into account cell proliferation during the course of treatment*.

Both hypo-fractionated schedules are also accelerated protocols in which the total dose is delivered in 32 or 18 days vs. the standard schedule delivered over 39 days. Accounting for tumor proliferation that will take place during the additional treatment (Travis and Tucker, [@B24]; Fowler, [@B8]; Stanton et al., [@B21]; Haustermans et al., [@B10]) as presented in Table [1](#T1){ref-type="table"}, the inclusion of a cell proliferation correction factor produces small decreases in the BEDs for the standard treatment. Therefore, taking into consideration tumor proliferation during treatment, an alpha/beta of 4 corresponds to equivalent tumor control probability among the three schedules.

The BED calculations for the 5wCB schedule estimate a slightly higher rate of early effects, erythema and desquamation and of late telangiectasia and fibrosis as compared with the standard fractionation schedule. Conversely, the BED calculations of the 3wCB schedule estimate a lower rate of acute effects of erythema, desquamation, and comparable late effects to those of standard fractionation.

Prone patient set-up and computed tomography simulation
-------------------------------------------------------

All patients were placed in the prone position on a dedicated treatment platform for computed tomography (CT) planning and treatment. The platform, placed on top of the CT couch, contains an open aperture on one side to allow for the index breast to fall away from the chest wall. Before the patients lay down prone on the platform for CT scanning, they were positioned supine and a radiation oncologist placed fiducial markers on their skin to clinically define the medial, lateral, caudal, and cephalad breast field borders. Subsequently, non-contrast CT images were acquired at 2.5--3.75 mm-thick intervals, from the level of the mandible to below the diaphragm. Details on the NYU prone technique were previously reported (Huppert et al., [@B12]).

Treatment planning for the standard 6-week RT schedule
------------------------------------------------------

The standard schedule consisted of a 2-Gy daily fraction delivered 5 days a week to a dose of 46 Gy to the whole breast, followed by a SB to the lumpectomy cavity treated either supine with en-face electrons or, less frequently, prone using photon tangents fields prone. Field definition to treat the entire breast was based on the following: opposed tangent photon beams were used to treat the entire breast tissue as identified at CT, in the prone position from midline and with the posterior edge of the field extending to the anterior edge of the latissimus dorsi muscle laterally.

The prone whole breast plans were created with two, three, or four fields using a field in-field technique and enhanced dynamic wedges as necessary using 3D-CRT planning. The boost target volume was contoured using evidence of the persisting surgical cavity at CT simulation and/or based on review of original patient records including mammography, ultrasound, magnetic resonance imaging, and operative records.

Treatment planning for concomitant boost schedules (5wCB and 3wCB definition of planning target volumes)
--------------------------------------------------------------------------------------------------------

Patients in the 5- and 3-week CB regimen were treated in the prone position using 6 MV photons using the technique of CB IMRT previously described (DeWyngaert et al., [@B6]). Patients in the 5-week schedule were treated with 50 Gy in 25 daily fractions of 2 Gy to the whole breast (PTV1) prescribed to the 100% isodose line with the tumor bed region (PTV2) boosted daily by an additional 0.25 Gy, using IMRT (total boost dose 6.25 Gy). For patients in the 3wCB protocol the whole breast (PTV1) was treated to a daily fraction dose of 2.7 Gy, with the tumor bed region (PTV2) boosted by an additional 0.5 Gy, using IMRT (total boost dose 7.5 Gy).

Separate non-coplanar IMRT fields were specifically designed to deliver the boost dose to the lumpectomy site on top of the ipsilateral whole breast dose planned using conventional 3D conformal techniques (Formenti et al., [@B7]). In the majority of patients, a two field IMRT field approach similar to mini-tangent non-coplanar beam arrangement was used to target the tumor bed. The whole breast plans were created using two or three fields, with enhanced dynamic wedges as necessary. These plans were used as a base plan for optimization of the boost fields. The optimization and calculations were done using Eclipse software (Varian Medical Systems, Palo Alto, CA, USA) using gradient-dependent optimization algorithm to satisfy dose-volume objectives and constraints for PTV1, PTV2, body, lung, and heart. The goals of planning were to deliver a CB to the tumor bed and to minimize the size of the hot spot volumes outside of PTV2. Planning constraints limited 5% of the heart volume to receive 18 Gy and 10% of the ipsilateral lung volume to receive less than 20 Gy.

Assessment of toxicities
------------------------

Acute skin toxicity was assessed by the treating radiation oncologist as a part of the standard weekly assessment, during radiation treatment, with the maximum toxicity scored during and within 90 days of radiation. Individual indices for acute skin toxicity like faint erythema, bright or brisk erythema, dry desquamation, and wet desquamation were noted. Late toxicity was assessed at least a year after radiotherapy and then yearly thereafter. For late skin toxicities, asymmetry, edema, telangiectasia, induration, hyper-pigmentation, and fibrosis were recorded. The reported toxicities score represents the maximal point of toxicity assigned during and after the radiation treatment or reported by the patient during and after RT completion.

Toxicities were scored according to the Radiation Therapy Oncology Group (RTOG)/the EORTC toxicity scale associated with radiation, and the late effects of normal tissue-subjective objective management analytical (LENT/SOMA) scale (Hoeller et al., [@B11]) for delayed toxicities as shown in Table [2](#T2){ref-type="table"}.

###### 

**Scoring for acute and late toxicities**.

  A. Acute radiation dermatitis                                                                                                                                                                                                                                                                                                                                                                                    
  -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------
  1                                                                                                        Faint erythema or dry desquamation                                                                                                                                                                                                                                                                      
  2                                                                                                        Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema                                                                                                                                                                                        
  3                                                                                                        Moist desquamation other than skin folds and creases; bleeding induced by minor trauma or abrasion                                                                                                                                                                                                      
  4                                                                                                        Skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site                                                                                                                                                                                                           
  5                                                                                                        Death                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                   
  **B. Late toxicity scoring according to the RTOG/EORTC and LENT/SOMA[\*](#tfn1){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                           **Grade 1**                                                                                                        **Grade 2**                                                                            **Grade 3**                                                                                   **Grade 4**
                                                                                                                                                                                                                                                                                                                                                                                                                   
  **RTOG/EORTC**                                                                                                                                                                                                                                                                                                                                                                                                   
  Skin                                                                                                     Slight atrophy, pigmentation change, some hair loss                                                                Patchy atrophy, moderate telangiectasia, total hair loss                               Marked atrophy, gross telangiectasia                                                          Ulceration
  Subcutaneous tissue                                                                                      Slight induration (fibrosis), and loss of subcutaneous fat                                                         Moderate fibrosis, but asymptomatic; slight field contracture, ≤10% linear reduction   Severe induration and loss of subcutaneous tissue, field contracture, ≥10% linear reduction   Necrosis
  **LENT/SOMA -- BREAST SUBJECTIVE**                                                                                                                                                                                                                                                                                                                                                                               
  Pain                                                                                                     Occasional and minimal hypersensation, pruritus                                                                    Intermittent and tolerable                                                             Persistent and intense                                                                        Refractory, excruciating
  **LENT/SOMA -- BREAST OBJECTIVE**                                                                                                                                                                                                                                                                                                                                                                                
  Telangiectasia                                                                                           \<1 cm^2^                                                                                                          1--4 cm^2^                                                                             \>4 cm^2^                                                                                     
  Fibrosis                                                                                                 Barely palpable, increased density                                                                                 Definite increased intensity and firmness                                              Very marked density, retraction, and fixation                                                 
  Edema                                                                                                    Asymptomatic                                                                                                       Symptomatic                                                                            Secondary dysfunction                                                                         
  Retraction, atrophy                                                                                      10--25%                                                                                                            \>25--40%                                                                              \>40--75%                                                                                     Whole breast
  **LENT/SOMA -- SKIN**                                                                                                                                                                                                                                                                                                                                                                                            
  Pigmentation change                                                                                      Transitory, slight                                                                                                 Permanent, marked                                                                      --                                                                                            --

*RTOG, Radiation Therapy Oncology Group; EORT, European Organization for Research and Treatment of Cancer; LENT/SOMA, late effects of normal tissue task force; SOMA, subjective, objective, management and analytic*.

*\*Hoeller et al. ([@B11])*.

Statistical methods
-------------------

Patient and disease characteristics were compared using pair-wise comparisons among the 3wCB, 5wCB, and 6wSB schedules using the Fischer's exact test using the SAS statistical software program. Pair-wise comparisons using Fischer's exact test were also performed to compare the three schedules with regard to acute and late toxicities.

Results
=======

From February 2003 to January 2005, 51 patients selected the standard 6wSB, 28 patients the 5wCB and 90 patients the 3wCB regimen. Patient characteristics are described in Table [3](#T3){ref-type="table"} that includes the results of pair-wise comparisons between the schedules, calculated by the Fisher's exact test using the SAS statistical software program.

###### 

**Distribution of baseline patient and tumor characteristics among the three groups of patients**.

  Demographics                             Standard 6wSB\* (*N* = 51)   AIMRT 5wCB^†^ (*N* = 28)   AIMRT 3wCB^††^ (*N* = 90)   5wCB vs. 6wSB\*\*   3wCB vs. 5wCB\*\*   3wCB vs. 6wSB\*\*
  ---------------------------------------- ---------------------------- -------------------------- --------------------------- ------------------- ------------------- -------------------
  **TUMOR STAGE I**                                                                                                                                                    
  T1a                                      51                           28                         90                          0.507               0.1864              0.5726
  T1b                                      45                           23                         82                          0.76                0.587               1
  T1c                                      35                           19                         63                          0.815               0.829               1
  **TUMORSTAGE II**                                                                                                                                                    
  T2a                                      9                            6                          17                          0.767               0.7877              1
  **NODAL STAGE**                                                                                                                                                      
  Negative                                 40                           26                         72                          0.122               0.1526              0.8312
  Positive                                 11                           2                          18                                                                  
  **HISTOLOGY**                                                                                                                                                        
  Ductal carcinoma                         50                           25                         79                          0.125               1                   0.0557
  Lobular carcinoma                        0                            2                          7                           0.123               1                   0.0487
  Mucinous carcinoma                       1                            1                          4                           1                   1                   0.6535
  **RACE**                                                                                                                                                             
  White                                    38                           19                         79                          0.603               0.0211              0.0612
  Black                                    5                            1                          6                           0.415               1                   0.5266
  Hispanic                                 6                            5                          3                           0.507               0.018               0.0715
  Asian                                    2                            2                          2                           0.34                0.0861              0.6202
  **TUMOR ESTROGEN RECEPTOR STATUS**                                                                                                                                   
  Negative                                 10                           14                         16                          0.01                0.0012              0.8233
  Positive                                 41                           14                         74                                                                  
  **TUMOR PROGESTERONE RECEPTOR STATUS**                                                                                                                               
  Negative                                 19                           20                         37                          0.005               0.0086              0.7217
  Positive                                 32                           8                          53                                                                  
  **TUMOR HER2/NEU STATUS**                                                                                                                                            
  Negative                                 40                           21                         85                          0.783               0.0071              0.0058
  Positive                                 11                           7                          5                                                                   
  **CHEMOTHERAPY**                                                                                                                                                     
  No                                       33                           19                         60                          0.81                1                   0.8544
  Yes                                      18                           9                          30                                                                  
  **ANTI-HORMONE THERAPY**                                                                                                                                             
  No                                       30                           18                         18                          0.81                2.80-05             5.82-06
  Yes                                      21                           10                         72                                                                  

*\*6wSB, 6-week sequential boost; ^†^5wCB, 5-week concomitant boost; ^††^3wCB, 3-week concomitant boost; \*\*Pair-wise comparisons were made between the 5wCB, 6wSB, and 3wCB schedules, using the Fischer's exact test*.

The patient and treatment characteristics were similar among the three groups regarding age (median 52, 54, and 57 for the standard, 5wCB and 3wCB groups, respectively), KPS, tumor and nodal staging, and histology. There were more white and fewer Hispanic patients treated with the 3wCB than the 5wCB schedule, *P* = 0.021 and *P* = 0.018, respectively. There were significantly less patients with estrogen receptor positive status in the 5wCB group than in the other groups (*P* \< 0.05), and significantly more HER2/NEU negative patients in the 3wCB cohort than in the other two groups (*P* \< 0.05). More patients in the 3wCB group received anti-hormone therapy as compared with both the 5wCB and 6wSB schedules (*P* \< 0.05). Finally, about the same ratio of patients in all three groups received chemotherapy (*P* = NS), in most cases consisting of a combination of doxorubicin, cyclophosphamide, and paclitaxel.

Acute toxicity
--------------

None of the patients underwent treatment breaks because of acute toxicity. Table [4](#T4){ref-type="table"} describes the incidence of acute toxicity during radiation therapy, consisting mainly of radiation dermatitis. Specifically, Grade 1 radiation dermatitis was observed in 27% of the recipients of 6wSB, 27% of 5wCB, and 58.5% of 3wCB. Grade 2 dermatitis was seen in 68.6% of patients on 6wSB, 73% of patients on 5wCB, and 8.1% of patients on 3wCB regimen. Grade 3 skin reactions were noted in 2 patients (4%) from 6wSB vs. one (0.9%) in the 3wCB regimen and in none of those treated with the 5wCB regimen. Figure [1](#F1){ref-type="fig"} demonstrates a patient who was treated with the 6-week standard fractionation regiment exhibiting Grade 2 brisk erythema at the end of treatment.

###### 

**Comparison of acute radiation toxicity among the three regimens**.

                             6wSB\* *N* = 51   5wCB^†^*N* = 28   3wCB^††^*N* = 90   5wCB vs. 6wSB\*\*   3wCB vs. 5wCB\*\*   3wCB vs. 6wSB\*\*
  -------------------------- ----------------- ----------------- ------------------ ------------------- ------------------- -------------------
  **BREAST PAIN**                                                                                                           
  Grade 1                    25                8                 1                  0.098               3.21--05            1.40--12
  Grade 2                    18                5                 0                  0.126               5.62--04            1.14E--09
  Grade 3                    3                 0                 0                  0.549               N/A                 0.0455
  **FATIGUE**                                                                                                               
  Grade 2                    8                 3                 1                  0.738               0.0411              0.0013
  Grade 3                    0                 0                 1                  N/A                 1                   1
  **RADIATION DERMATITIS**                                                                                                  
  Grade 1                    51                28                75                 N/A                 0.0204              0.0011
  Grade 2                    37                20                10                 1                   1.96--09            1.15--13
  Grade 3                    2                 0                 1                  0.537               1                   0.2965
  **BREAST EDEMA**                                                                                                          
  Grade 1                    15                12                14                 0.321               0.0041              0.0814

*\*6wSB, 6-week sequential boost; ^†^5wCB, 5-week concomitant boost; ^††^3wCB, 3-week concomitant boost. \*\*Pair-wise comparisons were made between the 5wCB, 6wSB, and 3wCB schedules, using the Fischer's exact test*.

![**Example of a patient treated with the 6wSB regimen demonstrating Grade 2 erythema during the final week of treatment, while receiving the sequential boost to the upper outer quadrant**.](fonc-02-00044-g001){#F1}

Pair-wise comparisons of acute complications with *P*-values less than 0.05 were chosen to detect when the data differed significantly in the 5wCB vs. 6wSB, 5wCB vs. 3wCB, and 6wSB vs. 3wCB schedules (Fisher's exact test, SAS statistical software program). All acute complications including breast pain, fatigue, and dermatitis were significantly less frequent among the patients in the 3wCB than in either the 5wCB or 6wSB schedule (*P* \< 0.05). Breast edema occurred less frequently among patients treated with the 3-week compared to the 5wCB schedule (*P* = 0.004), but not significantly less compared to the 6-week schedule (*P* = 0.081).

Figure [2](#F2){ref-type="fig"} describes the maximum incidence of acute skin toxicity among the three treatment groups: the 6wSB was associated with increased incidence of acute skin toxicity as compared with either the 3wCB or 5wCB schedules. The latter two had comparable patterns.

![**Acute toxicities: maximum incidence of erythema and desquamation between the three regimens: 6wSB (6-week sequential boost), 5wC (5-week concomitant boost), and 3wCB (3-week concomitant boost)**.](fonc-02-00044-g002){#F2}

All patients in the 6wSB and 5wCB schedule and most in the 3wCB developed Grade 1 dermatitis. As shown in Figure [3](#F3){ref-type="fig"}, at week 3 about 70% of patients on the 6wSB and 5wCB schedule developed Grade 2 dermatitis, while only 11% of patients on the 3wCB protocol. Also, Grade 3 dermatitis at the end of treatment occurred in 4% of patients on the 6wSB and 1% of patients on the 3wCB at the end of treatment.

![**Kinetics of Grade 2 and 3 acute toxicities**. Grade 2 toxicity (brisk erythema) was noticed at week 3 in 70% of patients in 5wCB and 6wSB schedules and in only 11% of the patients treated with 3wCB. Grade 3 dermatitis was seen in 1% of patients in the 3wCB and 4% of patients on the 6wSB schedule at 3 and 6weeks, respectively.](fonc-02-00044-g003){#F3}

Pain and fatigue were also more often experienced among recipients of the 6wSB regimen, with three patients experiencing Grade 3 pain. Twenty-five patients (49%) reported pain during 6wSB regimen compared to only eight patients (28.5%) in 5wCB and 1 (0.9%) in 3wCB group (*P* \< 0.05). Fatigue was also more pronounced among recipients of 6wSB: 15.7% compared to 10.7% in the 5wCB and 0.9% in 3wCB group (*P* \< 0.05 for 3wCB as compared to 5wCB and 6wSB). Patients in the 5wCB schedule exhibited more edema (43%) compared to 6wSB (29.4%) and 3wCB schedule (15.5%), with statistically significant increased edema seen for patients treated with 5wCB as compared with 3wCB (*P* \< 0.05).

Late toxicities
---------------

Late toxicities are listed in Table [5](#T5){ref-type="table"} with a median follow up of 61 months. A statistically significant difference in late grade ≥1 asymmetry was noted comparing the 3wCB and 5wCB schedule with conventional 6wSB, with reduced asymmetry noted in both accelerated schedules (*P* \< 0.05).

###### 

**Comparison of late toxicity among the three regimens, at 5-year median follow-up (*N* = 159 patients)**.

                           6wSB\* *N* = 46   5wCB^†^*N* = 23   3wCB^††^*N* = 90   5wCB vs. 6wSB\*\*   3wCB vs. 5wCB\*\*   3wCB vs. 6wSB\*\*
  ------------------------ ----------------- ----------------- ------------------ ------------------- ------------------- -------------------
  **ASYMMETRY**                                                                                                           
  Grade 1                  41                14                61                 0.01                0.622               0.007
  Grade 2                  8                 0                 9                  0.045               0.2                 0.274
  **PALPABLE MASS**                                                                                                       
  Grade 1                  3                 0                 11                 0.546               0.116               0.382
  Grade 2                  1                 0                 1                  1                   1                   1
  **INDURATION**                                                                                                          
  Grade 1                  26                12                61                 0.8                 0.222               0.257
  Grade 2                  3                 0                 9                  0.546               0.2                 0.751
  **FIBROSIS**                                                                                                            
  Grade 1                  14                5                 38                 0.572               0.093               0.197
  Grade 2                  2                 1                 8                  1                   0.683               0.494
  **TELANGIECTASIA**                                                                                                      
  Grade 1                  6                 4                 12                 0.721               0.738               1
  Grade 2                  1                 1                 5                  1                   1                   0.664
  Grade 3                  0                 1                 1                  0.333               0.367               1
  **HYPER-PIGMENTATION**                                                                                                  
  Grade 1                  24                16                41                 0.203               0.06                0.475
  Grade 2                  1                 0                 0                  1                   N/A                 0.338

*\*6wSB, 6-week sequential boost; ^†^5wCB, 5-week concomitant boost; ^††^3wCB, 3-week concomitant boost. \*\*Pair-wise comparisons were made between the 5wCB, 6wSB, and 3wCB schedules, using the Fischer's exact test*.

Late complications of telangiectasia, skin pigmentation, and fibrosis at 5 years were comparable among the three groups (*P* = NS). Grade III telangiectasia occurred in 1 patient treated by the 3wCB and in 1 patient in the 5wCB protocol.

Finally, 14% of patients treated with 6wSB regimen, 10% with the 5wCB and 25.8% of patients on 3wCB developed Grade 1 hyper-pigmentation changes: only one patient (0.6%) in the 6wSB developed Grade 2 hyper-pigmentation. Grade 1 fibrosis, defined as a barely palpable increased density compared to the other breast, was noted in 7% in the 6wSB, 2.5% in the 5wCB, and 19% in the 3wCB regimen. Grade 2 fibrosis was less common with the 6wSB (1.2%) and 5wCB (0.6%) compared to 3wCB regimen (5%).

Discussion
==========

Standard radiation dose fractionation for the treatment of early stage breast cancer has two main shortcomings: the inconvenience to patients who attend daily treatment for 6--7 weeks and the cost associated with a prolonged usage of the facilities. Among the strategies that have been employed to reduce the treatment time, the Canadian trial by Whelan et al. ([@B27], [@B28]) has generated solid evidence in favor of a hypo-fractionated, accelerated, whole breast irradiation for selected women with early stage breast cancer. However, at a non-planned subset analysis the hypo-fractionated regimen appeared to be less effective in patients with high-grade tumors, and it was associated at 10 years median follow up with a cumulative incidence of local recurrence of 15.6% compared to 4.7% among similar patients assigned to the standard fractionation group (*P* = 0.01; Smith et al., [@B20]).

Croog et al. reported the results in a consecutive series of 128 patients treated with a prone IMRT approach consisting of 16 daily fractions of 265 cGy to a total dose of 4,240 cGy followed by a conventionally fractionated boost, over 29 days. At a median follow-up of 18 months, one ipsilateral breast recurrence developed that was salvaged with mastectomy and immediate reconstruction (Croog et al., [@B4]).

Since 2003, we developed a series of research protocols testing feasibility and safety of a CB to the tumor bed, delivered by IMRT. Results from randomized trials have suggested that both local control of breast cancer and late change in breast appearance exhibit similar sensitivity to fraction size as modeled by the α/β ratio in the linear-quadratic formulation (Bentzen et al., [@B3]). Based on radiobiological modeling, we selected regimens that would provide biological effective dose equivalence to that of standard 6-conventional fractionation to 60 Gy using an α/β value of 4 for tumor control, and taking into consideration the different repopulation with a shorter, accelerated regimen (Rosenstein et al., [@B18]). Although BED modeling calculations for the 5wCB schedule estimated a slightly higher rate of early effects, erythema and desquamation and of late telangiectasia and fibrosis as compared with the standard fractionation schedule, this was not observed in this consecutive series of patients. In contrast, BED calculations of the 3wCB schedule estimated a lower rate of acute effects of erythema, desquamation, and a slight increase in fibrosis compared to conventional fractionation, as observed in the patients included in this report.

Other centers have also pilot-tested a CB accelerated fractionation regimen. At Fox Chase, 75 patients were treated with a hypo-fractionated regiment of IMRT in 20 treatments of 2.25 Gy per day for a total of 45 Gy over 4 weeks (Freedman et al., [@B9]). An electron boost was added, bringing dose to 2.8 Gy per fraction for a total of 56 Gy to the original tumor bed. Acute toxicity was tolerable with the majority of patients experiencing only Grade 1 skin toxicity. Late toxicity was not reported nor were the results compared to those obtained at the same institution when a standard fractionation regimen was utilized.

We previously reported the results of the 3wCB trial (Formenti et al., [@B7]), but no prospective comparison of the morbidity associated with different fractionation regimens utilizing a boost is available. While evidence to this regard would be best generated by a prospective randomized trial comparing the different fractionation regimens, the analysis of a consecutive cohort of patients with comparable characteristics and tumors, treated at the same institution, self-allocated to either of the three regimens can provide some initial information. The present analysis demonstrates reassuring preliminary data that late toxicity at 5 years of the 3wCB schedule is likely to be at least comparable, and acute toxicity appears to be less.

A 2010 Cochrane Collaboration Intervention Review (James et al., [@B14]) addressed the effects of altered fractionation size on women with early breast cancer who have undergone breast conservation surgery. Four randomized trials reported on 7095 women with node negative breast cancer, negative margin of surgical resection and tumors measuring less than 3 cm in diameter (89.8%). The results of this analysis demonstrated that compared to standard fractionation regimens, accelerated, hypo-fractionated radiation therapy (\>2 Gy per fraction) does not adversely affect the local recurrence risk ratio (RR 0.97, *P* = 0.78), breast appearance (RR 1.17, *P* = 0.09), or 5-year survival (RR 0.89, *P* = 0.16). Acute skin toxicity was found to be decreased with hypo-fractionation compared to standard fractionation (RR 0.21, *P* = 0.007). Many patients in the randomized trials included in the meta-analysis received a SB, after completing either hypo-fractionated or standard radiation. However, none of the studies analyzed compared a concurrent boost to a sequential one, as compared in this report.

Finally, current guidelines on the use of hypo-fractionated treatment tend to exclude patients who receive chemotherapy from consideration for hypo-fractionated treatment (Smith et al., [@B20]). There is only limited prospective data on the effect of chemotherapy on cumulative normal tissue toxicity after hypo-fractionated treatment as compared to conventional fractionation. As compared to Whelan et al. ([@B28]) study where 10.9% patients received chemotherapy, in this series, approximately a third of patients received chemotherapy, balanced among the three treatment groups (*P* = NS). There was no suggestion of increased toxicity among the patients who received chemotherapy and hypo-fractionation.

A limitation of the current report is the relatively short follow up, limited to 5 years. Whelan et al. ([@B27], [@B28]) demonstrated doubling of both skin (6 vs. 3%) and subcutaneous tissue (8 vs. 4%) toxicity with longer follow up. Similarly, among the patients treated in the EORTC 22881-10882 "boost vs. no boost" trial a trend toward a dose-dependent development of fibrosis was seen at 10 year follow-up: severe fibrosis occurred in 3.3% after a boost of 10 Gy, 4.4% after 16 Gy, and 14.4% after 26 Gy, respectively (Bartelink et al., [@B2]; Poortmans et al., [@B17]). Yarnold et al. ([@B30]) reported that patients who received a 14-Gy boost on the Royal Marsden Hospital/Gloucester Oncology Center (RMH/GOC) trial had a higher risk of breast induration and telangiectasia than those who did not receive a boost: however, there was no statistically significant difference between these groups in breast appearance, proportion of fair or poor cosmetic results, or risks of breast shrinkage, breast distortion, breast edema, arm swelling, or shoulder stiffness (Yarnold et al., [@B30]).

In this series, all patients were treated using a prone technique. All three treatments were regimens of 3D conformal radiation to the whole breast, with either an electron boost for the 6wSB schedule or an IMRT boost for the two accelerated schedules of CB to the tumor bed. Whether the prone approach permitted better conformality and dose homogeneity than standard supine set up remains to be established.

With a median follow up of 61 months, late toxicity was comparable among the three groups suggesting that the 3- or 5-week accelerated regimens utilizing CB, designed on solid BED predictions, are well-tolerated, with comparable toxicities to those derived from standard 6 week fractionation.
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